Romosozumab/CDP7851 for the treatment of osteoporosis

Expert Review of Endocrinology and Metabolism

Volumn 10, Issue 5, 2015, Pages 471-481

  Sim, Ie Wen ^a,b,c   Ebeling, Peter R ^c,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WESTERN HEALTH   (Australia)

^c SOUTHERN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

anabolic therapy; CDP7851; monoclonal antibody; romosozumab; sclerostin

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; ROMOSOZUMAB; SCLEROSTIN; WNT PROTEIN;

ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE REMODELING; CONSTIPATION; CORTICAL BONE; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INJECTION SITE REACTION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84940460050     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/17446651.2015.1079482     Document Type: Article

References (77)

1. Kanis JA. Assessment of osteoporosis at the primary health-care level. University of Sheffield: World Health Organization; 2007. Available from: www. who. int/chp/ topics/rheumatic/en/index. html
2. Kanis JA. Diagnosis of osteoporosis. Osteoporos Int 1997;7(Suppl 3):S108-16
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17(12):1726-33
4. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359(9321):1929-36
5. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137(9):1001-5
6. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ 1993;307(6914):1248-50
7. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Archives of osteoporosis 2013;8(1-2):136
8. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81(12):4358-65
9. van der Werff ten Bosch JJ, Bot A. Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med 1992;41(5-6):259-63
10. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
11. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
12. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10): 1479-91
13. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25(11): 2267-94
14. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24(8):1358-68
15. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009;20(10):1663-73
16. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007; 146(5):326-39
17. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41
18. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357(20):2028-39
19. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2003;19(2):415-32
20. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 2012; 27(12):2429-37
21. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009;284(16):10890-900
22. Balemans W, Van Hul W. Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Dev Biol 2002; 250(2):231-50
23. Kusu N, Laurikkala J, Imanishi M, et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003;278(26): 24113-17
24. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199(6):805-14
25. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22(23):6267-76
26. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19(13):1842-4
27. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22(1): 19-28
28. Krause C, Korchynskyi O, de Rooij K, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 2010;285(53):41614-26
29. Johnson ML, Kamel MA. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 2007;19(4):376-82
30. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108(6): 837-47
31. Sclerostin regulates RANKL expression in osteocytes. BoneKEy reports 2012;1:19
32. Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011;6(10):e25900
33. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/betacatenin signaling. J Bone Miner Res 2009; 24(10):1651-61
34. Sutherland MK, Geoghegan JC, Yu C, et al. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004; 35(2):448-54
35. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005;37(2): 148-58
36. Drake MT, Srinivasan B, Modder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010;95(11):5056-62
37. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010;95(4): 1991-7
38. Modder UI, Clowes JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 2011;26(1):27-34
39. Paccou J, Mentaverri R, Renard C, et al. The relationships between serum sclerostin, bone mineral density, and vascular calcification in rheumatoid arthritis. J Clin Endocrinol Metab 2014;99(12):4740-8
40. Ishimura E, Okuno S, Ichii M, et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 2014; 99(11):4315-20
41. Register TC, Hruska KA, Divers J, et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab 2014;99(1): 315-21
42. Arasu A, Cawthon PM, Lui LY, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 2012;97(6):2027-32
43. Ardawi MS, Rouzi AA, Al-Sibiani SA, et al. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The Center of Excellence for Osteoporosis Research Study. J Bone Miner Res 2012;27(12):2592-602
44. Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: The OFELY study. Osteoporos Int 2013;24(2):489-94
45. Clarke BL, Drake MT. Clinical utility of serum sclerostin measurements. BoneKEy reports 2013;2:361
46. Van Buchem FS, Hadders HN, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol 1955; 44(2):109-20
47. Truswell AS. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease. J Bone Joint Surg Br 1958;40-B(2):209-18
48. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human Mol Genet 2001;10(5): 537-43
49. Balemans W, Cleiren E, Siebers U, et al. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone 2005;36(6):943-7
50. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39(2):91-7
51. Beighton P, Barnard A, Hamersma H, van der Wouden A. The syndromic status of sclerosteosis and van Buchem disease. Clini Genet 1984;25(2):175-81
52. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005;90(12):6392-5
53. Stein SA, Witkop C, Hill S, et al. Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 1983;33(3):267-77
54. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88(12):5778-83
55. van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011;26(12):2804-11
56. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24(4):578-88
57. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010;25(12):2647-56
58. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25(5): 948-59
59. Marenzana M, Greenslade K, Eddleston A, et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone. Arthritis Rheum 2011; 63(8):2385-95
60. Hamann C, Rauner M, Hohna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013;28(3): 627-38
61. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26(5):1012-21
62. Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25(11):2412-18
63. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinol 2011; 152(9):3312-22
64. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95(4): 1838-45
65. Padhi D, Jang G, Stouch B, et al. Singledose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26(1): 19-26
66. Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study. J Clin Pharmacol 2013. [Epub ahead of print]
67. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370(5):412-20
68. McClung MR, Chines A, Brown J, et al. Effects of 2 Years of Treatment With Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density. J Bone Miner Res 2014; 29 (Supp 1). Available from: www. asbmr. org/education/AbstractDetailaid=9114bfe4-a51e-4e38-8a67-5d0deef408c6 [Last accessed 4 November 2014]
69. ClinicalTrials. gov [Internet]. Last updated May 9 CgIN. Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density. Available from: http://clinicaltrialsgov
70. Whitmarsh T, Treece G, Gee A, et al. Romosozumab and teriparatide effects on vertebral cortical mass, thickness and density in postmenopausal women with low bone mineral density (BMD). J Bone Miner Res 2014;29(Supp 1). Available from: www. asbmr. org/education/AbstractDetail aid=9114bfe4-a51e-4e38-8a67-5d0deef408c6. [Last accessed 23 February 2015]
71. Damm T, Libanati C, Pena J, et al. Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide: HR-QCT analyses of randomized controlled trial results in postmenopausal women with low BMD. J Bone Miner Res 2014; 29(Supp 1). Available from: www. asbmr. org/education/AbstractDetailaid=9114bfe4-a51e-4e38-8a67-5d0deef408c6. [Last accessed 23 February 2015]
72. Registrational Study With AMG 785 to treat postmenopausal osteoporosis (FRAME). Available from: https:// clinicaltrials. gov/ct2/show/NCT01575834
73. Study to determine the efficacy and safety of romosozumab in the treatment of postmenopausal women with osteoporosis. Available from: https://clinicaltrials. gov/ct2/ show/NCT01631214
74. An open-label study to evaluate the effect of treatment with AMG 785 or teriparatide in postmenopausal women (STRUCTURE). Available from: https://clinicaltrials. gov/ct2/ show/NCT01796301
75. Zhu D, Mackenzie NC, Millan JL, et al. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011;6(5):e19595
76. Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: A cross-sectional study. BMC Nephrol 2013;14:219
77. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. Lancet 2013;382(9886):50-6